154 related articles for article (PubMed ID: 2850327)
1. Clinical pharmacology of a new low molecular weight heparin (Alfa LMWH-Fluxum).
Dettori AG; Tagliaferri A; Dall'Aglio E; Pini M
Int Angiol; 1988; 7(3 Suppl):7-18. PubMed ID: 2850327
[TBL] [Abstract][Full Text] [Related]
2. Fibrinolytic and anticoagulant activity after a single subcutaneous administration of a low dose of heparin or a low molecular weight heparin-dihydroergotamine combination.
Grimaudo V; Omri A; Kruithof EK; Hauert J; Bachmann F
Thromb Haemost; 1988 Jun; 59(3):388-91. PubMed ID: 2847348
[TBL] [Abstract][Full Text] [Related]
3. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.
Scheuch G; Brand P; Meyer T; Herpich C; Müllinger B; Brom J; Weidinger G; Kohlhäufl M; Häussinger K; Spannagl M; Schramm W; Siekmeier R
J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic effects on blood coagulation of a new low molecular weight heparin (alfa-LMWH) in healthy volunteers and gynecological surgery patients.
Palareti G; Legnani C; Bianchini B; Guazzaloca G; Maccaferri M; Marabini A; De Iaco P; Marcozzi S; Mancini L; Orlandi C
Int Angiol; 1989; 8(1):47-52. PubMed ID: 2768958
[TBL] [Abstract][Full Text] [Related]
5. Dose response relationships of anticoagulant activities after subcutaneous administration of two low molecular weight heparins in healthy individuals.
Hellstern P; Kiehl R; von Blohn G; Köhler M; Meierhenrich U; Wenzel E
Thromb Haemost; 1986 Oct; 56(2):225-8. PubMed ID: 3810557
[TBL] [Abstract][Full Text] [Related]
6. Suppression of intimal hyperplasia with low molecular weight heparin in a sheep model.
Ao PY; Hawthorne WJ; Coombs R; Fletcher JP
Int Angiol; 1999 Jun; 18(2):131-9. PubMed ID: 10424369
[TBL] [Abstract][Full Text] [Related]
7. A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers.
Eriksson BI; Söderberg K; Widlund L; Wandeli B; Tengborn L; Risberg B
Thromb Haemost; 1995 Mar; 73(3):398-401. PubMed ID: 7667822
[TBL] [Abstract][Full Text] [Related]
8. Time-course of anti-Xa effects of calcium heparin and low-molecular-weight heparin given s.c.: insights for thrombosis prevention.
Romeo G; Salanitri G; Catania G
Drugs Exp Clin Res; 1988; 14(6):423-7. PubMed ID: 2850903
[TBL] [Abstract][Full Text] [Related]
9. Comparison of low molecular weight heparins and unfractionated heparin after successive subcutaneous administration. A randomized controlled study in healthy volunteers.
Pindur G; Heiden M; Köhler M
Arzneimittelforschung; 1993 May; 43(5):542-7. PubMed ID: 8392345
[TBL] [Abstract][Full Text] [Related]
10. The pharmacological profile of the low molecular weight heparin 21-23 in man: anticoagulant, lipolytic and protamine reversible effects.
Harenberg J; Stehle G; Dempfle CE; von Hodenberg E; Heene DL
Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):967-80. PubMed ID: 2483715
[TBL] [Abstract][Full Text] [Related]
11. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
Mischke R; Grebe S
Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
[TBL] [Abstract][Full Text] [Related]
12. Chrono-pharmacological study of once daily curative dose of a low molecular weight heparin (200 IU antiXa/kg of Dalteparin) in ten healthy volunteers.
Mismetti P; Reynaud J; Tardy-Ponce B; Laporte-Simitsidis S; Scully M; Goodwyn C; Queneau P; Decousus H
Thromb Haemost; 1995 Aug; 74(2):660-6. PubMed ID: 8585003
[TBL] [Abstract][Full Text] [Related]
13. Heparin and fibrinolysis--comparison of subcutaneous administration of unfractionated and low molecular weight heparin.
Eriksson E; Wollter IM; Christenson B; Stigendal L; Risberg B
Thromb Haemost; 1988 Apr; 59(2):284-8. PubMed ID: 2838926
[TBL] [Abstract][Full Text] [Related]
14. Anticoagulant effect at the time of epidural catheter removal in patients receiving twice-daily or once-daily low-molecular-weight heparin and continuous epidural analgesia after orthopedic surgery.
Douketis JD; Kinnon K; Crowther MA
Thromb Haemost; 2002 Jul; 88(1):37-40. PubMed ID: 12152674
[TBL] [Abstract][Full Text] [Related]
15. [Absence of transplacental passage of Fraxiparin (low molecular weight heparin) during the 3d trimester of pregnancy].
Forestier F; Daffos F; Rainaut M; Toulemonde F
J Gynecol Obstet Biol Reprod (Paris); 1987; 16(8):981-6. PubMed ID: 2836497
[TBL] [Abstract][Full Text] [Related]
16. Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins.
Alban S; Gastpar R
Thromb Haemost; 2001 May; 85(5):824-9. PubMed ID: 11372675
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of hemostatic and fibrinolytic alterations associated with daily administration of low-molecular-weight heparin for a 12-week period.
Lojewski B; Bacher P; Iqbal O; Walenga JM; Hoppensteadt D; Leya F; Fareed J
Semin Thromb Hemost; 1995; 21(2):228-39. PubMed ID: 7660145
[TBL] [Abstract][Full Text] [Related]
18. Oral administration of a microencapsulated low-molecular-weight heparin to rabbits: anti-Xa and anti-IIa profiles.
Javot L; Sapin A; Scala-Bertola J; Vigneron C; Lecompte T; Maincent P
Thromb Haemost; 2010 Jun; 103(6):1254-67. PubMed ID: 20390227
[TBL] [Abstract][Full Text] [Related]
19. Effects of standard heparin and a low molecular weight heparin (Kabi 2165) on fibrinolysis.
Agnelli G; Borm J; Cosmi B; Levi M; ten Cate JW
Thromb Haemost; 1988 Oct; 60(2):311-3. PubMed ID: 2851195
[TBL] [Abstract][Full Text] [Related]
20. Unfractionated heparin and CY 216: pharmacokinetics and bioavailabilities of the antifactor Xa and IIa effects after intravenous and subcutaneous injection in the rabbit.
Briant L; Caranobe C; Saivin S; Sié P; Bayrou B; Houin G; Boneu B
Thromb Haemost; 1989 Jun; 61(3):348-53. PubMed ID: 2552603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
